Immunotherapy vs. targeted therapy in first-line treatment of mutation positive metastatic melanomas: How does one choose?

Date 25 November 2018
Event ESMO Asia 2018 Congress
Session New horizons in radiotherapy for the management of sarcomas
Topics Melanoma
Anticancer Agents
Personalised/Precision Medicine
Immunotherapy
Presenter Rick L. Haas
Authors R.L. Haas
  • Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL